<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03920540</url>
  </required_header>
  <id_info>
    <org_study_id>GC1111_P3</org_study_id>
    <nct_id>NCT03920540</nct_id>
  </id_info>
  <brief_title>A Study of GC1111 in Hunter Syndrom Patients</brief_title>
  <official_title>Phase 3, Double-blind, Randomized, Active-controlled (Part 1) and Open-labeled, Historical Placebo Controlled (Part 2) Study to Evaluate the Efficacy of Hunterase (Idursulfase-beta) in Hunter Syndrome (Mucopolysaccharidosis II) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy of GC1111 in Hunter Syndrome Patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 6-MWT</measure>
    <time_frame>at Week 53 from baseline</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Hunter Syndrome</condition>
  <arm_group>
    <arm_group_label>GC1111</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects should receive the GC1111 for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All subjects should receive the comparator for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>GC1111</intervention_name>
    <description>GC1111 is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.</description>
    <arm_group_label>GC1111</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Comparator</intervention_name>
    <description>Comparator is 0.5mg per kg of body weight once weekly to be administered slowly by intravenous infusion.</description>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with Hunter syndrome

          -  Male at the age of â‰¥ 5

          -  Adequate abilities (including 6-MWT) to participate in this study in the opinion of
             the investigator.

          -  Voluntarily signed written informed consent to participation in this study

          -  Consent to contraception

        Exclusion Criteria:

          -  Prior treatment with iduronate-2-sulfatase ERT

          -  History of bronchotomy, bone marrow trasplanation, or cord blood transplanation.

          -  Known hypersensitivity reactions to any of the components of the invetigational
             product

          -  Prior or planned administration of other investigational products within 30 days
             before treatment with the investigational product in this study or duirng this study.

          -  Unable to perform 6-MWT.

          -  Female
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DongKyu Jin, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsug Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Gyu Jin</last_name>
      <phone>82-2-3410-3695</phone>
    </contact>
    <investigator>
      <last_name>Dong-Gyu Jin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2019</study_first_posted>
  <last_update_submitted>April 23, 2019</last_update_submitted>
  <last_update_submitted_qc>April 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GC1111</keyword>
  <keyword>Mucopolysaccharidosis II</keyword>
  <keyword>MPS II</keyword>
  <keyword>idursulfase-beta</keyword>
  <keyword>IDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

